Glaxo Profit Rises for First Time Since 2013, Tops Estimates

  • Sales of blockbuster medicine Advair plunges 19 percent
  • Shares climb by 2.2 percent, most in three weeks, in London

Glaxo CEO: Price Pressure Continues in United States

GlaxoSmithKline Plc reported its first increase in quarterly profit since 2013, as demand for its vaccines and new drugs helped offset declines in the sales of its blockbuster Advair.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.